Results 211 to 220 of about 64,978 (265)

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.

JAMA Netw Open
Camacho-Arteaga L, Iacoboni G, Kwon M, Bailén R, Hernani R, Benzaquén A, López-Corral L, Pérez-López E, Leguízamo-Martínez LM, Calvo-Orteu M, Guerreiro M, Balaguer-Rosello A, Alonso-Martínez C, Vidal X, Barba P, Agustí A.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lymphoma classification update: B-cell non-Hodgkin lymphomas

Expert Review of Hematology, 2017
Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex.
Andrew Feldman, N Nora Bennani
exaly   +3 more sources

Novel treatments in B cell non-Hodgkin’s lymphomas

BMJ, 2022
ABSTRACT The improved understanding of lymphoma biology and recent advances in the field of cancer immunology have paved the way for the development of many effective small molecule inhibitors and immunotherapies in B cell non-Hodgkin’s lymphomas.
Yazeed, Sawalha, Kami, Maddocks
openaire   +2 more sources

Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Best Practice & Research Clinical Haematology, 2006
Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the radiosensitivity of non-Hodgkin lymphoma (NHL) cells. There are now two radioimmunoconjugates (RICs) - ibritumomab tiuxetan (Zevalin) and tositumomab (Bexxar) - that are approved by the FDA in the US for relapsed low-grade or follicular B-cell NHL.
Grzegorz S, Nowakowski, Thomas E, Witzig
openaire   +4 more sources

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

European Journal of Nuclear Medicine, 2001
In the past decade, several new antibody-based therapies - using either radiolabelled or unlabelled monoclonal antibodies - have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by ...
Postema, E.J., Boerman, O.C., Oyen, W.J.G., Raemaekers, J.M.M., Corstens, F.H.M.   +4 more
openaire   +3 more sources

Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update

Seminars in Nuclear Medicine, 2023
Systemic radioimmunotherapy (RIT) is arguably the most effective and least toxic anticancer treatment for non-Hodgkin lymphoma (NHL). In treatment-naïve patients with indolent NHL, the efficacy of a single injection of RIT compares with that of multiple cycles of combination chemotherapy.
Francesco Cicone, Giulia Santo, Caroline Bodet-Milin, Giuseppe Lucio Cascini, Françoise Kraeber-Bodéré, Caroline Stokke, Arne Kolstad   +6 more
openaire   +3 more sources

Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma

Hematology, 2000
AbstractThe rapid increase in the incidence of the B cell non-Hodgkin's lymphomas (NHL) and improved understanding of the mechanisms involved in their development renders timely a review of the theoretical and practical aspects of molecular abnormalities in B cell NHL.In Section I, Dr.
Elizabeth, Macintyre, Dennis, Willerford, Stephan W., Morris   +2 more
openaire   +2 more sources

Laryngeal Manifestation of B-Cell Non-Hodgkin Lymphoma

Acta Otorrinolaringologica (English Edition), 2012
Laryngeal lymphomas are rare, involving less than 1% of all laryngeal tumours. Extranodal non-Hodgkin lymphomas generally appear in places where lymphoid tissue exists, such as the small bowel or parotid; they are very unusual in organs with little or no presence of lymphoid tissue, such as the larynx.
Jhonder Xavier, Salazar Guilarte, Manuela, Sancho Mestre, Juan Ramón, Gras Albert   +2 more
openaire   +2 more sources